Status:
COMPLETED
Respiratory Physiotherapy in Severe COVID-19 Patients
Lead Sponsor:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Conditions:
COVID-19
Eligibility:
All Genders
18-80 years
Brief Summary
COVID-19 is an infectious disease caused by SARS-CoV2 virus. COVID-19 patients can develop a severe disease that can lead to hypoxic respiratory failure and acute respiratory distress syndrome (ARDS)....
Detailed Description
COVID-19 is an infectious disease caused by SARS-CoV2 virus, that first appeared in China in 2019 and in Italy in February 2020. Approximately 80% of people infected with COVID-19 have mild to modera...
Eligibility Criteria
Inclusion
- Having laboratory confirmed COVID-19 pneumonia
- Developed hypoxemic acute respiratory failure (hARF) requiring access to ICU
- Treated by respiratory physiotherapists during the hospitalization period
Exclusion
- Previously documented neurological or neuromuscular diseases
- Passed over 1 month in bed before COVID-19 diagnosis
- Documented cognitive impairment (mini mental state examination \<24)
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2020
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT04459819
Start Date
March 1 2020
End Date
September 30 2020
Last Update
February 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Pathophysiology and Transplantation, University of Milan Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy, 20122